FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2036800446> ?p ?o ?g. }

• W2036800446 endingPage "e107995" @default.
• W2036800446 startingPage "e107995" @default.
• W2036800446 abstract "TH-302 is a hypoxia-activated prodrug (HAP) of bromo isophosphoramide mustard that is selectively activated within hypoxic regions in solid tumors. Our recent study showed that intravenously administered bolus pyruvate can transiently induce hypoxia in tumors. We investigated the mechanism underlying the induction of transient hypoxia and the combination use of pyruvate to potentiate the anti-tumor effect of TH-302.The hypoxia-dependent cytotoxicity of TH-302 was evaluated by a viability assay in murine SCCVII and human HT29 cells. Modulation in cellular oxygen consumption and in vivo tumor oxygenation by the pyruvate treatment was monitored by extracellular flux analysis and electron paramagnetic resonance (EPR) oxygen imaging, respectively. The enhancement of the anti-tumor effect of TH-302 by pyruvate treatment was evaluated by monitoring the growth suppression of the tumor xenografts inoculated subcutaneously in mice. TH-302 preferentially inhibited the growth of both SCCVII and HT29 cells under hypoxic conditions (0.1% O2), with minimal effect under aerobic conditions (21% O2). Basal oxygen consumption rates increased after the pyruvate treatment in SCCVII cells in a concentration-dependent manner, suggesting that pyruvate enhances the mitochondrial respiration to consume excess cellular oxygen. In vivo EPR oxygen imaging showed that the intravenous administration of pyruvate globally induced the transient hypoxia 30 min after the injection in SCCVII and HT29 tumors at the size of 500-1500 mm(3). Pretreatment of SCCVII tumor bearing mice with pyruvate 30 min prior to TH-302 administration, initiated with small tumors (∼ 550 mm(3)), significantly delayed tumor growth.Our in vitro and in vivo studies showed that pyruvate induces transient hypoxia by enhancing mitochondrial oxygen consumption in tumor cells. TH-302 therapy can be potentiated by pyruvate pretreatment if started at the appropriate tumor size and oxygen concentration." @default.
• W2036800446 created "2016-06-24" @default.
• W2036800446 creator A5011980329 @default.
• W2036800446 creator A5014699467 @default.
• W2036800446 creator A5021329884 @default.
• W2036800446 creator A5026838871 @default.
• W2036800446 creator A5038506360 @default.
• W2036800446 creator A5042870042 @default.
• W2036800446 creator A5049839861 @default.
• W2036800446 creator A5067831265 @default.
• W2036800446 creator A5069203516 @default.
• W2036800446 creator A5071225088 @default.
• W2036800446 creator A5072939048 @default.
• W2036800446 creator A5076638374 @default.
• W2036800446 creator A5079930078 @default.
• W2036800446 creator A5081250782 @default.
• W2036800446 creator A5082346230 @default.
• W2036800446 creator A5090075053 @default.
• W2036800446 date "2014-09-25" @default.
• W2036800446 modified "2023-09-27" @default.
• W2036800446 title "Pyruvate Induces Transient Tumor Hypoxia by Enhancing Mitochondrial Oxygen Consumption and Potentiates the Anti-Tumor Effect of a Hypoxia-Activated Prodrug TH-302" @default.
• W2036800446 cites W1968009184 @default.
• W2036800446 cites W1974357631 @default.
• W2036800446 cites W1995289673 @default.
• W2036800446 cites W1996830477 @default.
• W2036800446 cites W2005619963 @default.
• W2036800446 cites W2024903578 @default.
• W2036800446 cites W2026921059 @default.
• W2036800446 cites W2029206767 @default.
• W2036800446 cites W2034072253 @default.
• W2036800446 cites W2037397309 @default.
• W2036800446 cites W2057895959 @default.
• W2036800446 cites W2070480944 @default.
• W2036800446 cites W2079142824 @default.
• W2036800446 cites W2082594665 @default.
• W2036800446 cites W2091723288 @default.
• W2036800446 cites W2104928951 @default.
• W2036800446 cites W2105653042 @default.
• W2036800446 cites W2108623236 @default.
• W2036800446 cites W2118170166 @default.
• W2036800446 cites W2118585316 @default.
• W2036800446 cites W2124496728 @default.
• W2036800446 cites W2125257427 @default.
• W2036800446 cites W2126669622 @default.
• W2036800446 cites W2132907499 @default.
• W2036800446 cites W2157607856 @default.
• W2036800446 cites W2159564611 @default.
• W2036800446 cites W2320542539 @default.
• W2036800446 cites W2328719907 @default.
• W2036800446 doi "https://doi.org/10.1371/journal.pone.0107995" @default.
• W2036800446 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4177858" @default.
• W2036800446 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25254649" @default.
• W2036800446 hasPublicationYear "2014" @default.
• W2036800446 type Work @default.
• W2036800446 sameAs 2036800446 @default.
• W2036800446 citedByCount "35" @default.
• W2036800446 countsByYear W20368004462014 @default.
• W2036800446 countsByYear W20368004462015 @default.
• W2036800446 countsByYear W20368004462016 @default.
• W2036800446 countsByYear W20368004462017 @default.
• W2036800446 countsByYear W20368004462018 @default.
• W2036800446 countsByYear W20368004462019 @default.
• W2036800446 countsByYear W20368004462020 @default.
• W2036800446 countsByYear W20368004462021 @default.
• W2036800446 countsByYear W20368004462022 @default.
• W2036800446 countsByYear W20368004462023 @default.
• W2036800446 crossrefType "journal-article" @default.
• W2036800446 hasAuthorship W2036800446A5011980329 @default.
• W2036800446 hasAuthorship W2036800446A5014699467 @default.
• W2036800446 hasAuthorship W2036800446A5021329884 @default.
• W2036800446 hasAuthorship W2036800446A5026838871 @default.
• W2036800446 hasAuthorship W2036800446A5038506360 @default.
• W2036800446 hasAuthorship W2036800446A5042870042 @default.
• W2036800446 hasAuthorship W2036800446A5049839861 @default.
• W2036800446 hasAuthorship W2036800446A5067831265 @default.
• W2036800446 hasAuthorship W2036800446A5069203516 @default.
• W2036800446 hasAuthorship W2036800446A5071225088 @default.
• W2036800446 hasAuthorship W2036800446A5072939048 @default.
• W2036800446 hasAuthorship W2036800446A5076638374 @default.
• W2036800446 hasAuthorship W2036800446A5079930078 @default.
• W2036800446 hasAuthorship W2036800446A5081250782 @default.
• W2036800446 hasAuthorship W2036800446A5082346230 @default.
• W2036800446 hasAuthorship W2036800446A5090075053 @default.
• W2036800446 hasBestOaLocation W20368004461 @default.
• W2036800446 hasConcept C126322002 @default.
• W2036800446 hasConcept C150903083 @default.
• W2036800446 hasConcept C178790620 @default.
• W2036800446 hasConcept C185592680 @default.
• W2036800446 hasConcept C207001950 @default.
• W2036800446 hasConcept C2779081379 @default.
• W2036800446 hasConcept C509974204 @default.
• W2036800446 hasConcept C540031477 @default.
• W2036800446 hasConcept C71924100 @default.
• W2036800446 hasConcept C7836513 @default.
• W2036800446 hasConcept C86803240 @default.
• W2036800446 hasConcept C98274493 @default.
• W2036800446 hasConceptScore W2036800446C126322002 @default.
• W2036800446 hasConceptScore W2036800446C150903083 @default.

• next